FDA Approves Amgen's XGEVA(TM) (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Bone ...
Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA(TM) (denosumab), the first and only RANK Ligand inhibitorfor the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6 month priority review by the FDA, a designation reserved for drugs that offer major advances in ...
Read more on Medical News Today
Orignal From: FDA Approves Amgen's XGEVA(TM) (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Bone ...
Post a Comment